
CLAIMS

1. A compound of Formula (Iac-1) :




(Iac-1),or a solvate, or pharmaceutically acceptable salt thereof, wherein:


R_2 is $–(CH_2)_n$-**R_{2S}**, wherein n is 0, 1, or 2, and;

R_{2S} is 4- to 8-membered monocyclic heterocycloalkyl optionally substituted with one or more C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, halo, -CN, -OH, -O(C_1-C_6 alkyl), -NH_2, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or oxo; and

each **R_{3S}** is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, halo, or C_3-C_8 heterocycloalkyl wherein the C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, or C_3-C_8 heterocycloalkyl is optionally substituted with –O(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, halo, or -CN.



2. The compound of claim 1, wherein **R_{2S}** is oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, or azepanyl, wherein the oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, or azepanyl is optionally substituted with one or more C_1-C_6 alkyl, C_1-C_6 haloalkyl, or oxo; or further optionally






.


3. The compound of claim 1 or claim 2, wherein at least one $\mathbf{R_{3S}}$ is C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, halo, or C_3-C_8 heterocycloalkyl wherein the C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, or C_3-C_8 heterocycloalkyl is optionally substituted with –O(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, halo, or -CN.

4. The compound of claim 3, wherein at least one $\mathbf{R_{3S}}$ is , , or , methyl, ethyl, isopropyl, -CH_2OCH_3, -CH_2CF_3, -$CH_2CH_2OCH_3$, -CH_2CN, CH_2CF_2, or -$CH_2CH_2N(CH_3)_2$.


5. The compound of any one of claims 1-4, wherein the compound is of Formula (Iabc-1), (Iabc-1a), or (Iabc-1b):



(Iabc-1);




(Iabc-1a); or



(Iabc-1b);

or a solvate, or pharmaceutically acceptable salt thereof, wherein $\mathbf{R_{2S}}$ and $\mathbf{R_{3S}}$ are as described in claim 1.





6. The compound of any one of claims 1-5, wherein the compound is of Formula (Iabc-1a):













(Iabc-1a)







or a solvate, or pharmaceutically acceptable salt thereof, wherein $\mathbf{R_{3S}}$ is as described in claim 1.







7. The compound of any one of claims 1 to 6, being selected from:







Compound No.	Structure
1	
2	
3	
4	







5	
6	
7	
8	
10	







11	
14	
15	
16	
22	







23	
24	
25	
26	
27	
28	







29	
30	
31	
32	
33	
34	







35	
36	
37	
38	
39	
41	








42	
43	
44	
45	
46	
47	








50	
51	
52	
55	
56	
57	


59	
60	
61	
62	
63	
64	

65	
67	
68	
74	
78	
79	

82	
83	
84	
85	
99	
103	

107	
110	
111	
118	
120	
121	
122	

123	
135	
136	
138	
139	
150	
151	

152	

and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising the compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

9. A compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof for use in therapy.

10. Use of compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease or disorder which is an inflammatory disorder, an autoinflammatory disorder, an autoimmune disorder, a neurodegenerative disease, or cancer.

11. The use of claim 10, wherein the disease or disorder is an inflammatory disorder, an autoinflammatory disorder or an autoimmune disorder; optionally, the disease or disorder is selected from cryopyrin-associated auto-inflammatory syndrome (CAPS; e.g., familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome/ neonatal-onset multisystem inflammatory disease (NOMID)), familial Mediterranean fever (FMF), nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gout, rheumatoid arthritis, osteoarthritis, Crohn's disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), fibrosis, obesity, type 2 diabetes, multiple sclerosis, dermatological disease (e.g., acne) and neuroinflammation occurring in protein misfolding diseases (e.g., Prion diseases).

12. The use of claim 10, wherein the disease or disorder is a neurodegenerative disease; optionally, the disease or disorder is Parkinson's disease or Alzheimer's disease.

13. The use of claim 10, wherein the disease or disorder is cancer; optionally, the cancer is metastasising cancer, brain cancer, gastrointestinal cancer, skin cancer, non-small-cell lung carcinoma, head and neck squamous cell carcinoma or colorectal adenocarcinoma.